A2780cis Cell Line human
Кат. номер |
93112517-RNA-5UG |
93112517-CDNA-20UL |
93112517-1VL |
93112517-DNA-5UG |
Human ovarian carcinoma
This cisplatin-resistant cell line has been developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (Sigma catalogue no. 93112519) to increasing concentrations of cisplatin. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. An increased ability to repair DNA damage as well as cytogenetic abnormalities has been observed. In order to retain resistance cisplatinum has to be added to the media every 2-3 passages. In addition to this matched pair of drug-sensitive/resistant cell lines an adriamycin-resistant cell line, A2780adr (Sigma catalogue no. 93112520), has been isolated from the same parental line A2780.
Toxicity testing, drug resistance studies
2780cis human cell line has been used to study the cytotoxic effects of platinum (II) complexes and gold (I)-triphenylphosphine complexes with hypoxanthine-derived ligands. It has also been used to study the effects of cancer-cell specific oligopeptides.
STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 13
D16S539: 11,13
D5S818: 11
D7S820: 10
THO1: 6
TPOX: 8,10
vWA: 15,16
RPMI 1640,+ 2 mM Glutamine, + 1 µm Cisplatin, + 10% Fetal Bovine Serum FBS, (cisplatinum only necessary every 2-3 passages).
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x10,000cells/cm using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Cells will attach slowly after resuscitation and take up to 7 days to reach confluency. Recommendation: resuscitate cells in media without cisplatin. Add after subculture of attached cells.
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Adriamycin is a registered trademark of RDF Pharmacia & Upjohn S.P.A.
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
biological source | human ovary |
growth mode | Adherent |
karyotype | Modal no. 46 |
morphology | Epithelial |
products | Not specified |
receptors | Not specified |
application(s) | cell culture | mammalian: suitable |
relevant disease(s) | cancer |
shipped in | dry ice |
storage temp. | −196°C |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |